Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $29.05M |
| Net Income (Most Recent Fiscal Year) | $4.35B |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 105.82 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.47 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2346.02% |
| Net Margin (Trailing 12 Months) | -225.71% |
| Return on Equity (Trailing 12 Months) | -14.45% |
| Return on Assets (Trailing 12 Months) | -13.29% |
| Current Ratio (Most Recent Fiscal Quarter) | 37.91 |
| Quick Ratio (Most Recent Fiscal Quarter) | 37.91 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.99 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.31 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.17 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.25 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 713.55M |
| Free Float | 657.18M |
| Market Capitalization | $8.06B |
| Average Volume (Last 20 Days) | 4.74M |
| Beta (Past 60 Months) | 1.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 64.76% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |